Kornimate/medical-research-clean huggingface dataset:
parenting intervention for pediatric obesity

Conditions: Childhood Obesity; Parenting

Summary: the purpose of this study is to see if educational videos about how to help children develop healthy behaviors, paired with treatment in a pediatric obesity clinic, can increase caregiver confidence and improve child behaviors and weight. caregivers of children between the ages of 4 and 11 years old who are new patients to a pediatric obesity clinic will be invited to take part in the study. all families will receive the standard treatment provided in the pediatric obesity clinic. half of the caregivers will be assigned to also watch a few educational videos every month for 3 months in between clinic visits.


Eligibility criteria:
inclusion criteria: * legal guardian of a new patient to the nemours pediatric obesity clinic * child with body mass index (bmi) greater than the 95th percentile for age and sex * child 4-11 years of age exclusion criteria: * not proficient in english or spanish * not able to access the internet on any type of device * child has a genetic syndrome or primary endocrine disorder associated with obesity * child is taking a medication known to impact weight

Keywords: childhood obesity parenting intervention video intervention healthcare delivery
ripretinib in combination with binimetinib in patients with gastrointestinal stromal tumor (gist)

Conditions: Gastrointestinal Stromal Tumors

Summary: multicenter, open-label phase 1b/2 study of ripretinib in combination with binimetinib in patients with gastrointestinal stromal tumor (gist). there will be 2 distinct parts in this study: dose escalation (phase 1) and expansion (phase 2).


Eligibility criteria:
inclusion criteria: 1. patients ≥18 years of age with advanced gist (unresectable or metastatic). 2. must have at least progressed on imatinib or have documented intolerance to imatinib. 3. patients must have an eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1. 4. patients must have a histologic diagnosis of gist. 5. if a female of childbearing potential, must have a negative pregnancy test. 6. adequate organ function and bone marrow function exclusion criteria: 1. received prior anticancer therapy within 14 days or 5× the half-life whichever is longer) prior to the first dose. 2. ongoing or prior participation in the dcc-2618-03-002 study. 3. prior therapy with ripretinib. 4. prior therapy with mek inhibitor. 5. history of certain ocular disorders. 6. history of clinically significant hepatobiliary disease. 7. known active central nervous system metastases. 8. history or presence of clinically relevant cardiovascular abnormalities. 9. systemic arterial or venous thrombotic or embolic events within 6 months of first dose. 10. history of acute or chronic pancreatitis 11. history of chronic inflammatory bowel disease or crohn's disease requiring intervention within 12 months of first dose. 12. gastrointestinal abnormalities including but not limited to: * inability to take oral medication, * malabsorption syndromes
effects of the anchor system in the postural stability

Conditions: Breast Cancer; Balance; Distorted

Summary: evaluate the effect of a balance rehabilitation program associated or not with the use of the anchor system, on the postural control of women undergoing breast cancer treatment.

the aim of this study is to compare the effects of an exercise program associated or not with a non-rigid instrument, called the anchor system, on the postural control of women undergoing breast cancer treatment. for this purpose, 80 women submitted to breast cancer treatment will be invited to participate, divided into four homogeneous groups, determined by the sample calculation: women submitted to breast cancer treatment in the age group of 35 to 59 years (young adult) with lymphedema (gajl), women in the same age group without lymphedema (gaj), women in the age group 60 to 80 years (elderly) with lymphedema (gil), and women in the same age group without lymphedema (gi). cognitive status will be assessed by the mini mental state examination. to assess the subsystems responsible for maintaining balance, the balance evaluation systems test (bestest) will be used, presented in order to guide clinical intervention, in addition to the falls efficacy scale -international (fes-i). the distribution of plantar pressure and balance will be assessed using baropodometry. for data analysis, a normality test and data distribution will be performed, in addition to a statistical test consistent with the appropriate intra and intergroup comparisons, with a significance level of 5%.

Eligibility criteria:
inclusion criteria: * women undergoing treatment for breast cancer, in the 35 to 59 age group with lymphedema, women in the same age group without lymphedema, women in the 60 to 80 age group with lymphedema, and women in the same age group without lymphedema. exclusion criteria: * women diagnosed with rheumatic-orthopedic diseases; with complaints of balance; with injury to the peripheral nervous system of upper or lower limbs.

Keywords: breast cancer lymphedema postural balance falls
a pilot study to evaluate a molecular method for plaque

Conditions: Plaque; Gingivitis

Summary: this study is to evaluate the sensitivity of the molecular method and its ability to split a stannous fluoride toothpaste versus a negative control.


Eligibility criteria:
inclusion criteria: in order to be included in the study, each subject must: * provide written informed consent to participate in the study; * be 18 years of age or older; * agree not to participate in any other oral/dental product studies during the course of this study; * agree to delay any elective dentistry (including dental prophylaxis) until the study has been completed; * agree to maintain their current oral hygiene routine between the screening and baseline visit and not to add/change their oral care products during this time; * agree to refrain from any form of non-specified oral hygiene during the treatment periods (after the baseline visit), including but not limited to the use of products such as floss or whitening products; * agree to return for all scheduled visits and follow study procedures; * must have at least 16 natural teeth; * be in good general health, as determined by the investigator/designee based on a review of the health history/update for participation in the study; * agree to refrain from all oral hygiene for at least 12 hours prior to each visit; * agree to refrain from eating, chewing gum, drinking and using tobacco for 4 hours prior to each visit; * have at least 20 bleeding sites (sites with a score of 1 or 2 on the gbi index); * have minimum 3 sampling sites with bleeding and pocket depth ≥3mm but not deeper than 4mm; * have minimum 3 sampling sites without bleeding and with pocket depth ≤2mm. exclusion criteria: subjects are excluded from study participation where there is evidence of: * have had a dental prophylaxis within 2 weeks of plaque sampling visits; * have taken antibiotics or used anti-gingivitis / anti-bacterial oral care products such as chlorhexidine or listerine within 2 weeks of plaque sampling visits; * have rampant caries, open or untreated caries, or advanced periodontitis requiring prompt treatment; * need an antibiotic prophylaxis prior to dental visits; * a history of hypersensitivity to oral care products containing stannous fluoride; * a history of hypersensitivity to dyes (from products containing food dyes); * present with any disease or condition(s) that could be expected to interfere with examination procedures or the subject's safe completion of the study; or * are pregnant (self-reported) or lactating.
dose-escalation of cellistem-oa in patients with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: a phase i dose-escalation trial to assess safety and efficacy of allogeneic msc based-treatment (cellistem-oa) in patients with symptomatic knee osteoarthritis


Eligibility criteria:
inclusion criteria: * patient between 30 and 75 years old * knee-oa kellgren lawrence grade i to iii * pain density according to visual analogue scale superior or equal to 50 mm * patelar condromalacia grade i to iii * stable joint with normal physical exploration exclusion criteria: * bilateral symptomatic disease * local or systemic infection * neoplasia * immunosuppression state * pregnancy * anticoagulant therapy * other types of arthritis * symptomatic disease of hip and/or spine * intra-articular infiltration with steroids in the last 3 months * intra-articular infiltration with hyaluronic acid in the last 12 months

Keywords: mesenchymal stromal cells
effect of intrathecal administration of hematopoietic stem cells in patients with amyotrophic lateral sclerosis (als)

Conditions: Amyotrophic Lateral Sclerosis

Summary: autologous cell therapy in patients with als can stimulate neuroplasticity, modifying the neurodegenerative process and stops the clinical progression of disease.

there is no more extensive information

Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of als according to el escorial criteria. diagnosis-time less than four years. * over 18 years old. forced vital capacity ≥ 40%. * one year of evolution. * adequate nutritional state exclusion criteria: * severe bulbar als involucre. * inadequate nutritional status. * spondylotic myelopathy, or abnormalities in imaging study. * having concomitant neurological or psychiatric disease. * systemic disease with poor-control. * history of treatment with steroids or immunoglobulins in the last year. * participate in the past three months in a clinical trial. * history of malignancy or cancer today. * intracranial hypertension. * clinical suggestive data of infection in the site of lumbar puncture. * tracheostomy. * use of mechanical ventilation. forced vital capacity less than 40%. hiv-seropositive or presence of antibodies against hepatitis b or c in the serological studies.

Keywords: als, stem cells
study of electroencephalogram (eeg) measurement during different stimulations of the lower urinary tract

Conditions: Healthy; Nonneurogenic Neurogenic Bladder Dysfunction; Neurogenic Bladder Dysfunction Nos

Summary: the purpose of this study is to investigate afferent and cortical activities during bladder filling under different stimulations of the lower urinary tract. the participants of the study are healthy test persons and patients with overactive bladder.


Eligibility criteria:
inclusion criteria: * right-handed * written informed consent exclusion criteria: * any psychological diseases * any renal, cardiac, and pulmonary diseases * pregnancy or breastfeeding * problems keeping calm for 60 minutes in the sitting position * medication influencing eeg or bladder function

Keywords: lower urinary tract sensory evoked potential contact heat evoked potential stimulation electroencephalogram cortical processing bladder sensations lower urinary tract dysfunction overactive bladder
unicentric retrospective analysis of a cohort of 602 young adult and adolescent patients (aja), aged 15 to 30 years, with haematological malignancies, and managed between 2000 and 2016

Conditions: Malignant Haemopathies; Acute Leukemia; Non-hodgkin Lymphoma; Hodgkin Lymphoma

Summary: unicentric retrospective analysis of a cohort of 602 young adult and adolescent patients, aged 15 to 30 years, with haematological malignancies, and managed between 2000 and 2016

the therapeutic results (response and survival) of young adult and adolescent patients with hematological malignancies are generally lower than those usually observed in adults over the age of 30, with equivalent treatment, particularly in lymphomatous pathology.the overall analysis of this large cohort of patients in its entirety, then by age groups (15-17 years, 18-25 years, 26-30 years) and pathology aims to describe the future of patients and patients. compare them to the results of the literature observed in this age group, and according to the therapeutic regimens administered (pediatric regimen or adult regimen).

Eligibility criteria:
inclusion criteria: * malignant hemopathies (acute leukemia, non-hodgkin's lymphoma, hodgkin's lymphoma) in primary care between 2000 and 2016. exclusion criteria: * not applicable

Keywords: malignant haemopathies acute leukemia non-hodgkin lymphoma hodgkin lymphoma young adults adolescent
a study of recombinant oncolytic virus m1(vrt106) in patients with solid tumors

Conditions: Solid Tumor

Summary: to evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus m1 (vrt106) in patients with locally advanced/metastatic solid tumors.

this study is an open-label, dose-escalation clinical study which aims to evaluate the safety and tolerability of it injections of vrt106 in subjects with locally advanced/metastatic solid tumors, as well as evaluating the biological distribution characteristics and biological effects of vrt106 (i.e., virus tissue distribution and shedding characteristics), evaluating immunogenicity of vrt106, and preliminarily exploring the anti-tumor effects of vrt106.

Eligibility criteria:
inclusion criteria: * subject voluntarily agrees to participate in this study and signs an institutional review board -approved informed consent prior to performing any of the screening visit procedures. * males and females at 18-75 years of age, inclusive, at the screening visit. * subjects must have histological or cytological diagnosis of locally advanced or metastatic solid tumors who are intolerable or refractory to the standard therapy. * have at least one injectable lesion. * an eastern cooperative oncology group (ecog) score of 0-1. * an estimated survival time of ≥ 12 weeks. exclusion criteria: * subject has received any anti-tumor treatment 4 weeks before using the imp. * subject has received any prior oncolytic viruses or other gene therapies. * subject has a history of primary or acquired immunodeficient states, leukemia, lymphoma, acquired immunodeficiency syndrome (aids) or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy. * subject has received immunomodulatory drugs, including but not limited to thymosin, il-2, ifn, etc. within 14 days prior to first administration of imp.
outcome after soft tissue realignment of the tibial insertion of the patella tendon

Conditions: Patella Dislocation

Summary: soft tissue realignment of the tibial insertion of the patella tendon is a simple operative technique for treating dislocation of the patella in childhood and adolescence. it is performed in children with either recurrent dislocation or complicated primary dislocation in cases with malalignment or maltracking of the patella and a lateralised tibial tuberosity. it can be performed in patients with open epiphyses. we investigate long-term outcome after this procedure.

method. investigation of the outcome of a relatively new method for centralisation of the insertion of the patella tendon in patients with open epiphyses. using a soft tissue technique the patella tendon is released from the tibial tuberosity with the tendon still fixed to the distal periosteum. the tibial periosteum is split on the lateral border of the tibia distally. together with lateral release this procedure releases the patella tendon which finds a new insertion more medially. because the tendon is still fixed at the distal periosteum no additional fixation is needed and therefore no complications occur at the tibial apophysis due to osteosynthetic material. full weight bearing is possible after 4 weeks and movement is not restricted.results. from 1999 to 2004 a total of about 90 operations in about 80 patients for soft tissue centralisation of the distal insertion of the patella tendon were carried out on children and adolescents aged between 10 and 18 years old. this study is a retrospective analysis of the outcome after 6 to 10 years. relevant outcome criteria will be evaluated with the occurrence of recurring dislocation, the lysholm score, the tegner activity scale and subjective measurement with the vas scale and an additional functional outcome score, that we created especially for children. eventual occurrence of growth disturbance or osteoarthritis will be documented be clinical or radiological features.

Eligibility criteria:
inclusion criteria: * operative procedure soft tissue realignment performed between 1999 and 2004 exclusion criteria: * syndromal patella dislocation * genetic disorders

Keywords: centralisation patella dislocation open epiphyses malalignment syndrome relapse rate
multiple ascending dose study to evaluate the safety, tolerability of dc371739 treatment in hypercholesterolemic

Conditions: Hypercholesterolemia

Summary: this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of dc739 after multiple-dose oral administration, to explore the clinical effective dose, and to initially explore the efficacy and safety in hypercholesterolemia subjects.

totally about 30-50 qualified subjects were assigned to one of the following dose groups：20mg, 40mg, 60mg, 80mg, 120 mg (60mg and 120mg is the optional dose group). each of the dose groups will include 10 subjects (8 for dc739 and 2 for placebo). subjects will be admitted for treatment on day -1 and receive the first dose of study drug or placebo on day 1 and then treat for 28 days. subjects from different dose groups were enrolled in turn, the next dose group is conducted on the premise that the d15 safety evaluation was completed after the administration of the previous dose group with the result was tolerance. blood samples will be collected on day 1 for 48 hours and day 28 for 72 hours after administration for pharmacokinetic data analysis. blood lipid will be collected for effectiveness evaluation. pcsk9 and angptl3, urine and feces were collected for explore analysis.

Eligibility criteria:
inclusion criteria: * men and women aged 18 to 65 years (inclusive 18 and 65); * body mass index of 18 to 32 kg/m2(inclusive); * hypercholesterolemia subjects with ldl-c≥2.6mmol/l(100mg/dl); * male or female subjects who had no immediate plans to have children, the serum pregnancy test of women was negative at the time of screening, and agreed to use strict contraceptive measures throughout the study period and up to 6 months after the last dose; exclusion criteria: * ecg confirmed that the qt interval was prolonged \> 450ms (qt interval corrected for heart rate by bazetts formula \[qtcb\]); * use of statins (lovastatin, simvastatin, pravastatin, mevastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin, pitavastatin, etc.) , ezetimibe, xuezhikan, and other lipid-lowering treatment within 2 months prior to screening; use of pcsk9 monoclonal antibodies , fibric acid drugs (such as fenofibrate, gemfibrozil) and probucol within 3 months prior to screening; * use of warfarin, systemic steroids, cyclosporine, or other immunosuppressive therapy within months prior to screening; * subjects with hiv-ab , hbsag, anti-tp , hcv-ab positive; * a history of prescription drug abuse and illicit drug abuse within 6 months prior to screening; * a history of alcohol abuse within 6 months prior to screening;

Keywords: hypercholesterolemia pharmacokinetics pharmacodynamics
β3-adrenoreceptor as prognostic marker in neuroblastoma and ewing sarcoma

Conditions: Neuroblastoma; Ewing Sarcoma

Summary: this study on biological samples of patients affected by neuroblastoma and ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.


Eligibility criteria:
inclusion criteria: * diagnosis of ewing sarcoma or neuroblastoma exclusion criteria: * sieropositivity
investigation of clinical effectiveness of propolis extracts as food supplements in patients with sars-cov-2(covid-19)

Conditions: SARS-CoV2 Infection

Summary: primary purpose: to investigate the effect of propolis, a food supplement product, on healing parameters in patients with covid 19. secondary purpose: to provide a new supportive treatment in covid 19 treatment. in the present study to examine the effect of the use of propolis on healing parameters (laboratory and imaging) in patients with covid 19; propolis, which has antiviral properties, has also been used in humans in the covid19 pandemic as of 2020. however, in these studies, an alcohol-soluble extract of propolis was used. despite the disadvantages of its use in alcohol, it is clear that water and olive oil extracts of propolis are safer for humans. therefore, water extracts of propolis will be used in the study.


Eligibility criteria:
inclusion criteria: * patients over the age of 18 who do not need a ventilator who are inpatient in the covid service * patients under the age of 60 who do not need a ventilator who are inpatient in the covid service exclusion criteria: * patients do not have oral intake * patients whose informed consent form is not approved * patients who need a ventilator * pregnant women * children
benefits of high flow nasal cannula oxygen for preoxygenation during intubation in non severely hypoxemic patients

Conditions: Need for Intubation, No Severe Hypoxemia

Summary: the aim of this study is to determine whether high flow nasal cannula (hfnc) oxygen is more efficient than the standard high flow face mask (hffm) for preoxygenation before orotracheal intubation after crash induction in non severely hypoxemic patients

this study will be designed as followed : patients will be randomized in 2 groups : high flow nasal cannula "hfnc" or standard high flow face mask "hffm". patients randomized in "hfnc" group will receive a four minutes preoxygenation period with nasal high flow therapy (60 l/mn , fraction of inspired oxygen (fi02) = 100%) before orotracheal intubation under laryngoscopy after crash induction. after induction and during laryngoscopy, hfnc will be maintained in an attempt to achieve apneic oxygenation. patients randomized in "hffm" group will received a four minutes preoxygenation period with standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. after induction, hffm will be removed, enabling laryngoscopic vision

Eligibility criteria:
inclusion criteria: * adults older than 18 years regardless of the gender * requiring orotracheal intubation in intensive care unit * "no severely hypoxemic respiratory failure" defined as oxygen pression (pa02)/fi02 \> 200 mmhg measured in the 4 hours before inclusion exclusion criteria: * not the first intubation during this stay in intensive care unit * contraindication to oro-tracheal intubation * intubation without anaesthesic rapid sequence induction * intubation during cardiac arrest * real emergency (as asphyxia) with immediate intubation needed (without time enough for randomization) * nasopharyngeal obstacle with contraindication to use optiflow device * patients with a documented cormack iv exposition before inclusion * protected adult * pregnancy or breastfeeding * lack of consent * patient already enrolled in another study that could interfere with the primary objective of this study

Keywords: non severely hypoxemic respiratory failure preoxygenation crash induction